Interleukin-13 acts as an apoptotic effector on lung epithelial cells and induces pro-fibrotic gene expression in lung fibroblasts

Clin Exp Allergy. 2008 Apr;38(4):619-28. doi: 10.1111/j.1365-2222.2008.02944.x. Epub 2008 Feb 11.

Abstract

Background: IL-13 promotes acute allergic asthma and is discussed to play a role in late asthmatic features such as fibrotic processes and airway remodelling. The contributions of IL-13-mediated mechanisms to subepithelial events related to fibrosis are not yet settled.

Objective: We investigated the impact of IL-13 on lung epithelial cells as apoptotic effector and on lung fibroblasts as inducer of pro-fibrotic gene expression.

Methods: Using the two lung epithelial cell lines A549 and BEAS-2B as well as primary lung epithelial cells, we investigated the capability of IL-13 to induce apoptosis by both flow-cytometry and ELISA. The ability of IL-13 to increase the expression of pro-fibrotic genes and to exert influence on the expression of its own receptor was investigated by real-time quantitative PCR measurement of mRNAs encoding collagen I, collagen III, basic fibroblast growth factor (bFGF), alpha-smooth muscle actin (alpha-SMA) and the IL-13 receptor alpha1 (IL-13Ralpha1) chain in human primary lung fibroblasts. The specificity of IL-13-mediated cellular responses was confirmed by means of an inhibitory monoclonal antibody directed to the IL-13 receptor.

Results: IL-13 induces apoptosis in lung epithelial cell lines as well as in primary lung epithelial cells. Furthermore, IL-13 increases the expression of mRNA for alpha-SMA and collagen III, but not for bFGF in human primary lung fibroblasts. The susceptibility of lung fibroblasts to IL-13-induced up-regulation of pro-fibrotic genes is associated with the regulation of IL-13 receptor expression. IL-13-dependent fibrosis-associated effects could be inhibited by antibody-mediated blockade of the IL-13Ralpha1 subunit.

Conclusion: Our findings indicate a function of IL-13 as a mediator in fibrotic processes leading to loss of functional airway tissue in asthma. They also highlight the therapeutic potential of specifically targeting the interaction between IL-13 and its receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actins / drug effects
  • Actins / genetics
  • Antibodies, Blocking
  • Antibodies, Monoclonal / pharmacology
  • Apoptosis / drug effects*
  • Cells, Cultured
  • Collagen Type III / drug effects
  • Collagen Type III / genetics
  • Dose-Response Relationship, Drug
  • Enzyme-Linked Immunosorbent Assay
  • Epithelial Cells / drug effects*
  • Epithelial Cells / pathology
  • Fibroblasts / drug effects*
  • Fibroblasts / metabolism
  • Fibroblasts / pathology
  • Fibrosis / genetics*
  • Flow Cytometry
  • Gene Expression / drug effects*
  • Gene Expression Profiling
  • Humans
  • Interleukin-13 / pharmacology*
  • Interleukin-4 / pharmacology
  • Lung / cytology
  • RNA, Messenger / drug effects
  • RNA, Messenger / genetics
  • Receptors, Interleukin-13 / antagonists & inhibitors
  • Receptors, Interleukin-13 / drug effects
  • Receptors, Interleukin-13 / genetics
  • Reverse Transcriptase Polymerase Chain Reaction
  • Signal Transduction / drug effects
  • Up-Regulation / drug effects

Substances

  • ACTA2 protein, human
  • Actins
  • Antibodies, Blocking
  • Antibodies, Monoclonal
  • Collagen Type III
  • Interleukin-13
  • RNA, Messenger
  • Receptors, Interleukin-13
  • Interleukin-4